No Data
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
12 Health Care Stocks Moving In Wednesday's Intraday Session
RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability
Rapt Therapeutics Is Maintained at Neutral by UBS
UBS Maintains RAPT Therapeutics(RAPT.US) With Hold Rating, Cuts Target Price to $2
UBS analyst Eliana Merle maintains $RAPT Therapeutics(RAPT.US)$ with a hold rating, and adjusts the target price from $10 to $2.According to TipRanks data, the analyst has a success rate of 42.0%
Express News | RAPT Therapeutics Inc : UBS Cuts Target Price to $2 From $10